Base editing, a new player in the gene editing arena, could have an important role in the development of immune-based cell therapies to treat solid tumors. Using cell therapies, such as CAR-T cells, in solid tumors remains challenging: the current word on the street is that such chimeric antigen receptors (CARs) will need multiple gene modifications to make them efficient and it is in this space that base editing could have a substantial advantage.Immune-cell-based therapy is an exciting cell therapy approach to treat cancer where the natural defenses of a patients immune system are used to target and kill cancer cells. Hopes were high following the initial FDA approvals of the first autologous CAR-T therapies for Novartis KYMRIAH (Aug 2017) and Gilead/Kite Pharmas YESCARTA (Oct 2017), both for blood-based cancers, but translating these successes into solid tumors remains a challenge. This is a consequence of the complexity and heterogeneity of solid tumors together with the immune inhibitory nature of the tumor microenvironment.For T cell-based therapies to work, the patient is treated with modified T cells that are rendered capable of identifying and killing tumor cells and, through this, generating a wider immune response against the tumor. Two key approaches used to modify T cells are through expressing a T cell receptor (TCR) known to target the tumor cell or a CAR. Other approaches include using and/or modifying natural killer cells, gamma delta cells or tumor infiltrating lymphocytes. It is not clear which approach will provide the most effective treatment option and in fact it might be that each tumor type responds better to one approach or to a combination of approaches. Irrespective of the approach, it is clear that the current therapies all face similar challenges; the risk of graft vs host disease (GvHD), a lack of durable remissions, on-target or off-target toxicity and cytokine release syndrome.Another layer of complexity for T cell-based therapies lies with the source of T cellsusing the patients own (autologous T cells), or a donor or iPSC-derived T cells (allogeneic). Each approach has advantages and challenges. Briefly, autologous treatments are attractive because they mitigate the risk of immune rejection and GvHD when infused back into the patient. However, they require a complex manufacturing process that necessitates specialist equipment local to the patient to enable the isolation of their T cells followed by rapid manufacture to transform them into engineered T cells ready to infuse back into the patient. At all points during this manufacturing pipeline, the product must be kept sterile and tracible to ensure the correct cells are transfused back into the correct patient. The allogeneic T cells approach is appealing because of the possibility that these could be engineered to be universal donor cells (suitable for all or most patients). Such cells can be manufactured in bulk and administered to multiple patients all over the world. This bulk manufacturing would attract cost-savings once a critical mass of therapy is reached. It could also allow for engineered T cells to be available on-tap to any patient, a game-changer for particular patients whose own T cell count is either too low for engineering, or that transduce poorly with the engineered construct during manufacture. The challenge for allogeneic T cell therapies is the ability to generate cloaked T cells that do not provoke an immune-response in the patient, as this could kill the engineered T cells after transplantation such that they have no efficacy or potentially lead to the death of the patient as a result of a disseminated cytokine storm. Despite these challenges, in April 2019 the US Food and Drug Administration (FDA) approved the first allogeneic CAR-T for investigational use in patients with multiple myeloma and more are expected to follow.To try and achieve a stealth allogeneic T cell that flies under the radar of the patients immune system, genetic engineering is key. Although T cells can be engineered to express a specific TCR or CAR, additional genetic changes are required to provide a cloak of invisibility, prolong the survival of the cells in the patient and enable them to function in an immune suppressive tumor microenvironment. From a simplistic point of view, one could view the modified CAR or TCR as a sat nav, with the T cell being the engine. You need both to get to your destination and, if youre able to improve your engine, its possible the outcome could be achieved faster and in a more reliable fashion. There are several gene knockouts or gene knockdowns that are seen as a natural first step to improving the properties of engineered allogeneic T cells and these are summarized in the table below:As there are multiple gene knockout options, a gene engineering technology capable of making multiple gene edits with as few off-target effects as possible is needed. Indeed, it is conceivable that an effective allogeneic T cell-based therapy might require ten or more gene edits.This prompts the question What is the best gene editing platform or technology to support multiple gene edits? On the surface of it, and owing to its phenomenal adoption in research labs worldwide over the past decade, most currently use the gene editing approach provided by CRISPR-Cas9. CRISPR was first commercialized in 2012 and quite staggeringly made its debut in a clinical trial for cell therapy in June 2016. Although CRISPR is an efficient gene editing tool, its mode of action of generating double-strand breaks in the DNA could be a source of concern. DNA double-strand breaks, which tend to be repaired by the cells repair machinery in an error prone fashion, can cause unintended changes in the genome of engineered cells. Although there are methods for minimizing these off-target effects when single genes are targeted, targeting multiple genes in one cell all at the same time could lead to genome-altering insertions, deletions and/or chromosomal translocations. The impact of this on a patient could be that the cell therapy is effective but the off-target genetic changes lead to deleterious side-effects, impacting patient recovery and potentially survival. Well-known alternatives to CRISPR include transcription activator-like effector nucleases (TALENS) and zinc finger nucleases (ZFN). These approaches have slightly different safety profiles to CRISPR and while optimized for single gene edits or knockouts, multiple gene knockouts still present a challenge for these technologies. Freedom to operate using these technologies in the therapeutics space can also be challenging, particularly for start-up and biotech companies.The potential deleterious impact of off-target effects, particularly for multiple gene edits has opened the door to a newcomer on the gene engineering scene: base editing. This technology first gained prominence from peer-reviewed papers published by researchers from Harvard University.1 Others, such as Rutgers University, have also developed base editing platforms.2 In brief, base editing uses a deaminase enzyme to make a specific base pair change in the DNA. The base pair alteration can either be an A to G or a C to T depending on which deaminase is used. Importantly, the CRISPR-Cas system is used to guide the deaminase to the base pair that is going to be altered, but in this version of CRISPR-Cas, a DNA double-strand break is not made, meaning that the off-target effects with base editing in terms of insertions, deletions or translocations should be substantially reduced.On the surface, this crucial characteristic makes base editing an excellent choice of gene editor for cell therapyit can be used to specifically knock-out multiple genes through the introduction of stop codons or splice site disruptions with limited capacity to introduce substantial, large-scale chromosomal abnormalities. However, as base editing was first published in May 2016,1 substantial research is required to understand fully the utility of base editing in the therapeutic space and to appreciate its advantages and challenges compared with standard gene editing approaches, such as CRISPR-Cas, TALENs and ZFNs.As is somewhat expected of a fashionable area for scientific research, the gene editing space does not stand-still for very long: Prime editing has followed hot on the heels of base editing. Unlike base editing, which makes changes to specific base pairs in the DNA, prime editing allows changes to be made to a run of base pairs by forcing the cell to use a DNA copying system that exists naturally in cells as part of the DNA repair mechanism. Initial data suggest3 that prime editing has higher off-target effects compared with base editing, in terms of introducing insertions and deletions, and more work is needed to understand the comparison and utility of base editing vs. prime editing. It will be interesting to see how prime editing evolves over the months and years within the cell and gene therapy space.Although cell therapy has demonstrated its potential for driving complete remissions in some patients with hematological cancers, the next big step is to translate these early successes into patients with solid tumors. However, due to the complexity of solid tumors, this is not a simple or straight-forward process and multiple factors need to be considered. While the sat nav in the form of an engineered TCR or CAR is crucial, the T cell engine could be the natural starting point for improving efficacy in patients with solid tumors, as could the use of allogeneic rather than autologous approaches. The multiple edits that will be needed to deliver a stealth, engineered, allogeneic off-the-shelf T cell are only now being investigated in earnest and it could be that the new kid on the block, base editing, provides a compelling route forward.References1. Komor, A.C., Kim, Y.B., Packer, M.S., Zuris, J.A. and Liu, D.R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533(7603), 420424. Doi:10.1038/nature179462. Horizon Discovery to provide access to novel base editing technology, January 2020;https://horizondiscovery.com/en/news/2020/Horizon-Discovery-to-provide-access-to-novel-base-editing-technology (accessed May 2020)3. Anzalone, A.V., Randolph, P.B., Davis, J.R., et al. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576(7785), 149157. doi:10.1038/s41586-019-1711-4Dr. Jonathan Frampton is a business development professional who has been working for Horizon Discovery for the past 9 years and currently as their Corporate Development Partner. He is always scouting for exciting novel technology that could complement Horizons already extensive gene engineering toolkit. In addition to this he works closely with Horizons partners to manage out-licensing opportunities.

See more here:
Cell Therapy For Solid Tumors - Contract Pharma

Tom Farrell didnt have much to do after Bellicum announced in January 2017 that they were bringing in a new CEO. He had led the CAR-T company for over a decade, since before Carl Junes New England Journal of Medicinepaper had made cell therapy the hottest thing in cancer research. Now he was facing an 18-month non-compete.

So he worked quickly when, not long after that clock expired in 2018, a banker who helped take Bellicum public told him about a South Korean company called Green Cross LabCell that had built a natural killer cell factory and was looking to develop therapies off it. Farrell hopped a plane to Seoul.

It was hugely impressive, Farrell told Endpoints News.There was nothing [else] I came across that was truly disruptive from a business model perspective.

A year and a half later, Farrell has his new company. Called Artiva, it launches with $78 million in Series A funding and an exclusive deal with Green Cross to push some of their natural killer cell technology into the clinic. Theyll start with a therapy that combines NKs with an approved antibody therapy like rituximab to improve the antibodys effectiveness. Behind that, theyre working on CAR-NK therapy and, longer term, gene-edited CAR-NK cells. RA Capital Management, venBio and 5AM Ventures led the round.

Artiva joins what, after many years, has recently become a booming field. In February, MD Anderson showed that a Takeda-licensed CAR-NK therapy cleared tumors completely in 7 of 11 non-Hodgkins lymphoma patients. Two months later, J&J gave Fate Therapeutics, one of the earliest biotechs in the field, an up-to $3.1 billion deal for their CAR-NK and CAR-T therapies. The Big Pharmas are joined by a slate of recent upstarts, including Celularity, Nkarta, NantKwest, and Cytovia.

Unlike the other newcomers, Artiva makes virtually no claim on having original science. In fact, Farrell said, biotechs emphasis on novel technologies is part of why cell therapy has advanced only incrementally since the approval of the first two CAR-T therapies. Industry hasnt focused enough on addressing the manufacturing issues that have made therapies so costly and difficult to scale, he said.

Lewis Lanier, an immunologist at the University of California, San Francisco and an early pioneer in NK cell research, said Artiva would still face the same questions other drug developers face will some patient reject the cells? Will the natural killer cells actually last a significant amount of time after infusion? but the collaboration could give them an edge.

The Korean Green Cross manufacturing facility is really first rate, thats where the advantage is, Lanier, who is not involved in Artiva, told Endpoints. The science is really routine, theyre not doing anything particularly innovative.

For years, NK cells have been viewed as one of the key potential ways of making off-the-shelf cell therapy. Part of the innate immune system, implanting these cells from donors doesnt lead to the same resistance that donor T cells can. One of the problems, though, is that NKs are finicky, as Lanier puts it, vastly more difficult to grow and manipulate in a lab. Only recently have a couple companies figured out ways to do it consistently. Fate, for instance, uses master lines of iPSC stem cells.

At the Green Cross facility Farrell toured two Novembers ago, the South Korean company had refined a process to derive NK cells from donated umbilical cord blood and cryo-preserve it. A week after his tour, Farrell flew to San Diego for the ASH conference, where he ran into Pete Flynn, another longtime biotech executive out of a job. Flynn had run early development for Fate in its early years before leaving to run R&D for the anti-obesity company Orexigen, which had just gone bankrupt.

Farrell explained what he saw in Seoul and the two debated different approaches to off-the-shelf therapy. They figured the manufacturing base could be a launching pad.

Even though were a Series A company, were looking to become the go-to NK cell, Flynn, now COO, told Endpoints. Basically all the pieces are in place already, whereas for some of those other companies, there might still be some work to do.

View original post here:
Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to leapfrog natural killer...

Cell and gene therapy has evolved into one of the biopharma industry's hottest markets with a major splash of investment and a run of approvals likely in the coming years. To meet what's likely to be massive demand for manufacturing capacity, industry experts are calling for "forward-looking" investmentsbut as one pointed out, those checks aren't easy to write.

During a virtual roundtable Monday hosted by Fierce Pharma, manufacturing experts from Novartis, Gilead's Kite unit, BioMarin and Astellas' Audentes said building capacity and figuring out how to scale production would make the difference in whether the industry will be ready to handle a slate of expected approvals.

According to former FDA Commissioner Scott Gottlieb, the agency could approve between 10 and 20 cell and gene therapies a year through 2025 with as many as 800 such therapies moving through drugmakers' pipelines.

Chuck Calderaro, Kite's global head of technical operations, said Kite's primary concern was how to scale production of its cell therapy offerings, including Yescarta, the company's only approved therapy in the space.

VIRTUAL ROUNDTABLE: Up to the Challenge: Manufacturings Central Role in the Cell- and Gene-Therapy Revolution (reg. req'd)

Calderaro noted that Kite has a turnaround time of 16 days from patients having their blood drawn to infusionand the drugmaker is hoping to keep that figure stable as its manufacturing chain grows.

"Access to capacity is always a challenge in a growing area, and especially in cell therapy, which is personalized to order," Calderaro said. "The challenge for us is to be able to scale that excellence as we begin to globalize our cell therapy treatments."

The first challenge for Gilead will come from bringing its newest facility in Amsterdam online after the EU gave it the go-ahead earlier this month.

RELATED: Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online

Gilead's 117,000-square-foot CAR-T facility at SEGRO Park Amsterdam Airport won a green light after the European Medicines Agency (EMA) approved the plant's end-to-end manufacturing process. The site will house European production fo Yescarta, which won an EMA approval back in August 2018 to treat relapsed or refractory diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma.

Calderaro highlighted the Amsterdam facility as the "next step" in Gilead's global manufacturing ramp-up for Yescarta as the site will be able to churn out enough of the pricey therapy for 4,000 patients each year.

Gilead also plans to build a 67,000-square-foot facility at its Oceanside, California, biologics site just for developing viral vectors, the tools needed to deliver genetic material into cells. Calderaro said that facility would give Gilead "a little more control" of its supply chain as it looks to scale up.

RELATED: Pharma's gene and cell therapy ambitions will kick into high gear in 2020despite some major hurdles

Meanwhile, Steffan Lang, Novartis' head of technical operations, pointed out that building capacity for the future will go hand-in-hand with building an experienced team to lead into the future.

"Its about the people and capabilities," Lang said. "You have to have the right team in place to build capacity at the appropriate scale across the globe."

Novartis' gene therapy Kymriah was the first FDA-approved therapy of its kind back in August 2017. Since then, Novartis has expanded Kymriah's reach globally, including opening a new facility in Stein, Switzerland, that cleared up a transatlantic bottleneck for shipments to Novartis' facility in Morris Plains, New Jersey.

Meanwhile, BioMarin and Audentes are both pursuing first FDA approvals for their cell and gene therapy candidates and are looking to scale up manufacturing to make the leap into commercial.

RELATED: Audentes investing $109M in gene therapy manufacturing facility with 200 jobs

In February, Audentes announced it would invest $109 million into a 135,000-square-foot facility in Sanford, North Carolina to flesh out its cell and gene therapy manufacturing needs. The first phase is slated to take 18 months to build and will be operational by 2021. The rest of the investment will play out over two more years.

Donald Wuchterl, Audentes' SVP of technical operations, said building capacity would require a "forward-looking" approach to investingbut the lengthy timelines for these therapies make that foresight difficult.

"These are tough checks to write," Wuchterl said. "Were looking at potentially three years out in a field thats growing rapidlyit takes some constitution, I would say."

BioMarin, which is in the homestretch for an FDA approval for its hemophilia A gene therapy candidate valoctocogene roxaparvovec, or valrox, is in a similar boat looking to make the leap to commercial. For the Robert Baffi, special advisor to the company's CEO, scaling up manufacturing is a big taskbut he hopes that a "biology revolution" could provide a big breakthrough for production in the coming years.

"While I think there's improvements to be had on the manufacturing side today, I think there's a biology revolution still to come in terms of making the vectors more specific, more targeted, more preciseand that would be a big boon for the industry," he said.

The rest is here:
With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel - FiercePharma

DUBLIN--(BUSINESS WIRE)--The "CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies" report has been added to ResearchAndMarkets.com's offering.

This latest study report CAR T Cell Therapy Market Global Forecast by Regions (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII, Others), Clinical Trials/Study (CD19, CD20, GD2, CD22, CD30, CD33, HER1, HER2, MESO, EGFRvII), Companies (Novartis, Gilead Sciences (Kite Pharma), Celgene Corporation (Juno Therapeutics), Celyad) provides a detailed and comprehensive insight of the global CAR T cell therapy market.

For many years, the support of cancer therapy was chemotherapy, surgery and radiation therapy. However, in recent times, CAR-T cell therapy has been introduced as an incredibly supportive treatment for cancer patients. Since the introduction of chemotherapy, this treatment is one of the most significant breakthroughs. In this therapy, immune cells are collected from patients, and it is modified in the laboratory by doctors. After modification, these immune cells are infused back into the patient as they can easily recognize and kill cancer cells. These infused cells get multiplied and stay in the body as living drugs. According to analysis, CAR-T Cell Therapy Market is expected to be USD 7.4 Billion by the end of the year 2028.

Growth Factors for CAR-T Cell Therapy

Factors such as growing numbers of cancer in adults and children, and increasing policy initiatives to encourage cell therapy research in cancer, and increasing numbers of clinical trials worldwide are some of the main drivers for the global demand for CAR T cell therapy. The economic scenario in the CAR-T cell therapy industry is very dynamic, and key players compete with each other to gain access to major markets in the United States and Europe. Companies are seeking to secure treatment facilities to increase access for patients to their treatments.

Developments did by Companies in CAR T Cell Therapy

In 2017, a new milestone was set for oncology patients when the FDA approved the first two CD19-targeted known as (Chimeric Antigen Receptor) CAR T cell therapies produced by Novartis and Gilead Sciences known as Kite Pharma in the United States. Such two approvals have helped to improve the global demand for CAR T cell therapy because more companies are searching for this excellent opportunity to reach the marketplace. More than 200 CAR T clinical trials are ongoing or completed in various parts of the world. In 2018, Novartis announced its 33 approved centres in the U.S. and Gilead announced its 28 approved centres for the care of patients. Companies are also coming up with new developments in the field.

Key Topics Covered:

1. Executive Summary

2. Global Chimeric Antigen Receptor (CAR)-T cell Therapy Market

3. Market Share - CAR-T Cell Therapy

3.1 By Geographical Region

3.2 By Targeted Antigens

4. Targeted Antigen Market

4.1 CD19

4.1.1 Introduction

4.1.2 Market Size and Forecast

4.2 CD20

4.3 GD2

4.4 CD22

4.5 CD30

4.6 CD33

4.7 HER2

4.8 Mesothelin (MESO)

4.9 EGFRvIII

4.10 Others

5. Geographical CAR-T Cell Therapy Market (2016 -2026)

5.1 North America

5.2 Europe

5.3 Asia Pacific

5.4 Latin America

5.5 Middle East

5.6 Africa

6. Global - CAR-T Cell Clinical Trials/Study

6.1 CD19

6.2 CD20

6.3 CD22

6.4 CD30

6.5 CD33

6.6 EGFRvIII

6.7 GD2

6.8 HER1

6.9 HER2

6.10 MESO

7. China CAR-T Cells Clinical Trials Details

7.1 By Cities CAR-T Cells Clinical Trials

7.2 CD19 Directed CAR-T Cells Clinical Trials

7.3 Non-CD19 Directed CAR-T Cells Clinical Trials

7.4 Solid Tumors CAR-T Cells Clinical Trials

8. CAR-T Cell Therapy SWOT Analysis

8.1 Strength

8.2 Weakness

8.3 Opportunities

8.4 Threats

9. Regulation in CAR-T Cell Therapy

9.1 United States

9.2 European Union

9.3 China

10. IPO/Investment/Funding/Partnership in CAR-T Cell Therapy Market

10.1 Venture Capital Investment

10.2 Initial Public Offerings of CAR-T Companies

10.3 CAR-T Companies Strategic Partnerships/Deals

10.4 Key CAR-T Technology Deals

11. Growth Drivers

11.1 FDA Approvals of CAR-T Therapy

11.2 Dramatically Increasing Number of CAR-T Cell Trials Globally

12. Challenges

12.1 Regulatory Challenges

12.2 Very Expensive CAR-T Therapy Treatment

13. Novartis

13.1 Company Overview

13.2 Initiatives

13.2.1 Point 1

13.2.2 Point 2 Kymriah (tisagenlecleucel), First-in-class CAR-T Therapy from Novartis Received Second FDA Approval

13.2.3 Point 2

13.3 Financial Insight

14. Gilead Sciences (Kite Pharma)

14.1 Company Overview

14.2 Company Initiatives

14.2.1 Point 1

14.2.2 Point 2

14.3 Company Financial Insight

15. Celgene Corporation (Juno Therapeutics)

15.1 Company Overview

15.2 Company Initiatives

15.2.1 Point 1

15.2.2 Point 2

15.3 Company Financial Insight

16. Celyad

16.1 Company Overview

16.2 Company Initiatives

16.2.1 Point 1

16.2.2 Point 2

16.2.3 Point 3

16.3 Financial Insight

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/lssoan

Read the original post:
Global CAR T Cell Therapy Market to 2026 - by Regions, Targeted Antigens, Clinical Trials/Study & Companies - ResearchAndMarkets.com - Business...

The study titled Global Stem Cell Therapy Market Research Report includes detailed research undertaken by analysts as well as an in-depth analysis of the global market. A detailed, highly extensive study of this market alongside pivotal aspects that may impact the commercialization graph of this industry has been given in the study.

As per the latest research report, the global Stem Cell Therapy Market is anticipated to depict a CAGR of 10.2% through 2025, having recorded a valuation of 7.8 billion in 2018.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/3331

By 2025, the Stem Cell Therapy Market is expected to hit a remuneration of 15 billion. An extremely definite evaluation of the global market in terms of qualitative as well as quantitative analysis has been covered in this report. The myriad aspects of this industry, having considered its historical and forecast data have been enlisted in the study. Also, the research report is inclusive of substantial details with regards to an efficient SWOT analysis, PESTEL analysis, and Porters five force model of the market.

The Stem Cell Therapy Market report coverage includes numerous aspects like the market size, geographical growth opportunities, important vendors in the market, driving factors and constraints, segmental evaluation, and competitive landscape.

The report intends to enlist myriad updates and data with regards to the market alongside various growth opportunities which may help the global industry expand at an appreciable rate. An in-depth summary of the Stem Cell Therapy Marketcombined with a well-defined set of market definitions as well as outline of the industry have been given in the report.

In the report, the abstract section is inclusive of information on the market dynamics. This section is further categorized into driving factors propelling the market growth, industry hindrances, trends characterizing the market growth, as well as the business opportunities prevalent in the industry.

The Stem Cell Therapy Market report also contains information pertaining to the anticipated CAGR of the global business through the forecast period. In addition, many technological developments and innovations that may possibly boost the industry outlook over the anticipated period are also mentioned in the study.

Top Companies

Split by application, the market is divided into

This study is inclusive of in-depth information with respect to the consumption of the product as well as application segment market share, in tandem with the growth rate likely to be registered by every application segment.

Report Growth Drivers

What are the key highlights of this report?

More:
Stem Cell Therapy Market Share Research By Applications And Regions - News.MarketSizeForecasters.com

Following an initial trial, researchers concluded that UAECell19 reduced the duration of hospitalisation from 22 days to just six. Image Credit: iStock

Abu Dhab:The Abu Dhabi Stem Cell Centre (ADSCC) has now treated more than 2,000 patients suffering from COVID-19, with 1,200 already fully recovered from the effects of the virus.

ADSCC announced today that it had succeeded in ramping up the number of treatments from 73 in the initial clinical trials. The large increase was a result of a major effort by staff at the centre to treat as many people as possible, following the UAE Governments decision to make it available free of charge to all moderate-to-high risk COVID-19 patients in the country.

The Governments decision came after the treatment, branded UAECell19, demonstrated efficacy and an impressive safety profile was reflected in the absence of significant changes in adverse events reported, absence of any unexpected serious reactions (such as anaphylaxis, allergic reactions or sudden death) and an absence of any lung complications as determined by radiological exams from inhalation of the nebulised product.

A team of doctors and researchers at ADSCC, led by Dr Yendry Ventura, announced in May that they had developed a new treatment for COVID-19 patients. UAECell19, an autologous stem cell-based therapy, appears to help the body fight the virus and makes the virus less harmful.

Quicker recovery

Following an initial trial, researchers were able to conclude that UAECell19 reduced the duration of hospitalisation from 22 days to just six, when compared to patients who had received standard treatment.

Further analyses revealed that patients treated with the stem cells were 3.1 times more likely to recover in less than seven days than those treated with standard therapy, and 67 per cent of the patients who received stem celltreatment owed this recovery to the new treatment.

ADSCC has since secured intellectual property rights protection for UAECell19, which opens the way for the treatment to be shared widely so more patients can benefit from it.

ADSCC said researchers are at various stages of investigative efforts to establish effectiveness (Phase 3 trial), optimal efficacy of dosageand efficacy to treat other respiratory diseases such asthma, COPDand cystic fibrosis.

Continue reading here:
COVID-19: UAE treats 2000 virus patients with novel stem cell therapy - Gulf News

A new research study has been presented by Precision Market Reports (PMR) after a comprehensive analysis on AUTOLOGOUS CELL THERAPY Market where user can get benefits from the complete market research report with all required useful information on market. Report discuss all major market aspects with expert opinion on current market status along with historic data as well. Detailed study Price, Share, Size & Growth, Latest News & Developments, Expansion Plan, Current Business Strategy, Top Companies, Sales, Revenue & Competitors Analysis, Production and Consumption, Demand & Supply, Industry and Business Study, Effect of Covid 19 (Buyers & Sellers) and Prediction 2020-2025.

Regions Covered in the AUTOLOGOUS CELL THERAPY Market:

Covid-19 Scenario:

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the corona virus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

Top Players & Competitive Analysis (Benefits) for AUTOLOGOUS CELL THERAPY:

A competitive analysis is a strategy where we identify major competitors and research their products, sales, and marketing strategies. By doing this, you can create solid business strategies that improve upon your competitors. A competitive analysis helps you learn the ins and outs of how your competition works. It also helps you identify what theyre doing right and opportunities where you can easily one-up them by using a strategy they havent taken advantage of.Every brand can benefit from regular competitor analysis. By performing a competitor analysis, youll be able to:

As you can see, learning any of these four components will lead your brand down the path of achievement. But before you get too excited to start, we need to nail down a few important basics.

Once you identify your true competition, youll need to determine what metrics youll be comparing across the board. Below, well give nine specific factors to compare and tips on how to identify this competition in the first place.

AUTOLOGOUS CELL THERAPY Competitors Analysis includes market shares for all the companies listed below, Competitors Analysis revenue chart, Competitive Dashboard, and the competitors latest strategies for overcoming the Covid 19 pandemic situation.

Get A PDF Sample of AUTOLOGOUS CELL THERAPY Report: https://www.precisionmarketreports.com/download-sample/293752

SEGMENTAL ANALYSIS:

Business segment reporting breaks out a companys financial data by company divisions,subsidiaries, or other kinds of businesssegments. In an annual report, business segment reporting provides an accurate picture of apublic companysperformance to its shareholders. Management uses business segment reporting to evaluate the income, expenses, assets, and liabilities of each business division to assess its general healthincluding profitability and potential pitfalls.

Asegmentis a component of a business that generates its ownrevenuesand creates its own product, product lines, or service offerings.In general, if a unit of a business can be lifted out of the larger company and remain a self-sufficient entity, then it may be classified as a business segment.

By Market Players:BioTime, Pharmicell, BrainStorm Cell Therapeutics, Opexa Therapeutics, Vericel Corporation, Regeneus

By TypeBone Marrow, Epidermis

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

KEY TAKEAWAYS:

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, and Chart) @: https://www.precisionmarketreports.com/download-sample/293752

What Reports Provides:

Table of Contents:

1.1 Research Scope

1.2 Market Segmentation

1.3 Research Objectives

1.4 Research Methodology

1.4.1 Research Process

1.4.2 Data Triangulation

1.4.3 Research Approach

1.4.4 Base Year

1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth

1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections

1.5.2 Covid-19 Impact: Commodity Prices Indices

1.5.3 Covid-19 Impact: Global Major Government Policy

1.6 The Covid-19 Impact on AUTOLOGOUS CELL THERAPY Industry

1.7 COVID-19 Impact: AUTOLOGOUS CELL THERAPY Market Trends

2 GLOBAL AUTOLOGOUS CELL THERAPY QUARTERLY MARKET SIZE ANALYSIS

2.1 AUTOLOGOUS CELL THERAPY Business Impact Assessment COVID-19

2.1.1 Global AUTOLOGOUS CELL THERAPY Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2020-2025

2.2 Global AUTOLOGOUS CELL THERAPY Quarterly Market Size 2020-2021

2.3 COVID-19-Driven Market Dynamics and Factor Analysis

2.3.1 Drivers

2.3.2 Restraints

2.3.3 Opportunities

2.3.4 Challenges

3 QUARTERLY COMPETITIVE ASSESSMENT, 2020

3.1 By Players, Global AUTOLOGOUS CELL THERAPY Quarterly Market Size, 2019 VS 2020

3.2 By Players, AUTOLOGOUS CELL THERAPY Headquarters and Area Served

3.3 Date of Key Players Enter into AUTOLOGOUS CELL THERAPY Market

3.4 Key Players AUTOLOGOUS CELL THERAPY Product Offered

3.5 Mergers & Acquisitions, Expansion Plans

Any query? Enquire Here for Discount (COVID-19 Impact Analysis Updated Sample): https://www.precisionmarketreports.com/download-sample/293752

The study points out the limitations that aim to overcome the challenges to massive success for companies. Through means of this study, customers can conveniently obtain views on the AUTOLOGOUS CELL THERAPY market based on the current scenario.

What is the Impact of Covid-19 Outbreak on the AUTOLOGOUS CELL THERAPY?

About Precision Market Reports (PMR):

Precision Market Reports provides quantified B2B research on 25,000 high-growth niche opportunities / threats that will impact 50 to 75 percent of global company revenues. Actively representing more than 5000 customers worldwide, including 50 percent of Fortune 500 global businesses as clients. Almost 25,000 top officials across eight industries worldwide approach Precision Market Reports for their pain points around revenue decisions.

Our reports provide a rare combination of concrete perspectives and qualitative research to help businesses attain sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile extensive, interspersed with relevant data, market studies.

Precision Business Reports provide objective insight and reliable data, helping companies of all sizes take timely decisions. We tailor creative solutions for our customers to help them address problems that are distinct from their business. Our aim is to empower our customers with holistic market intelligence, giving them a granular overview of the market in which they operate.

Contact Person:Mr.Brian SmithPrecision Market Reports169, Elisenthal,North Rhine- Westphalia, Rhehin- Sieg- Kreis,Windeck, Hohnrath,Germany, DE- 51570.Phone:+1 (845) 377-0269Website:www.precisionmarketreports.comEmail:[emailprotected]/[emailprotected]

Go here to see the original:
AUTOLOGOUS CELL THERAPY Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2028|BioTime, Pharmicell, BrainStorm Cell...

The Cell Therapy Manufacturing Market Research Report 2020 published by Prophecy Market Insights is an all-inclusive business research study on the current state of the industry which analyzes innovative strategies for business growth and describes significant factors such as top developers/manufacturers, production value, key regions, and growth rate. Impact of Covid-19 pandemic on the market will be completely analyzed in this report and it will also quantify the impact of this pandemic on the market.

The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Cell Therapy Manufacturing market over the forecast period (2019-2029).

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Cell Therapy Manufacturing market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

The facts and data are represented in the Cell Therapy Manufacturing report using graphs, pie charts, tables, figures and graphical representations helping analyze worldwide key trends & statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21

The research report also focuses on global major leading industry players of Cell Therapy Manufacturing market report providing information such as company profiles, product picture and specification, R&D developments, distribution & production capacity, distribution channels, price, cost, revenue and contact information. The research report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Cell Therapy ManufacturingMarket Key Companies:

harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

The predictions mentioned in the Cell Therapy Manufacturing market report have been derived using proven research techniques, assumptions and methodologies. This market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

Segmentation Overview:

The report provides an in-depth analysis of the Cell Therapy Manufacturing market segments and highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market. Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis of market based on COVID-19 impact, detailed analysis on economic, health and financial structure.

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/21

Key Questions Answered in Report:

Stakeholders Benefit:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Cell-Therapy-Manufacturing-Market-21

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://medium.com/@varshashirode0000/global-blockchain-in-genomics-market-trends-analysis-and-forecast-till-2029-3f92b8bdc622

See the rest here:
Cell Therapy Manufacturing Market: Opportunities Forecast and Value Chain 2020-2030 - 3rd Watch News

Misleading claims of Covid-19 cure

Vincentius Aji Jatikusumo

The Jakarta Post, Indonesia

Researchers at Airlangga University (Unair) and the State Intelligence Agency (BIN) released on June 12 what appeared to be an encouraging statement: the discovery of five combination drug therapies and two stem cell therapies for treating Covid-19.

The joint statement also said that the medicines were ready for distribution to treat Covid-19 patients.

In theory, the drug combinations recommended by Unair and BIN have the potential to inhibit Sars-CoV-2. However, none of the recommended drugs have been proved in any clinical study to be a safe and effective treatment for Covid-19.

In fact, evidence exists that one of the drugs, hydroxychloroquine, may worsen the condition of patients. This led the World Health Organisation to suspend the clinical trial of the drug.

Unair and BIN are correct in conducting in vitro (test tube) experiments to verify the effect and toxicity of the drugs. Unfortunately, they have not communicated in any clear way on how they designed, executed and analysed their experiments.

Stem cell therapy is another Covid-19 treatment that Unair and BIN researchers have proposed.

However, stem cell therapy is still considered very risky, expensive and limited to treating a few cancers, such as leukaemia. No evidence exists that stem cell therapy is efficient in treating viral infections in the human body such as the coronavirus.

Unair's and BIN's valiant efforts should still be applauded, as they are committed to treating Covid-19 and ending the pandemic. However, everyone should realise that discovering treatments and developing a potential vaccine for a disease that was virtually unknown six months ago take a lot of time and resources.

Unair and BIN said that they had submitted their research to at least seven peer-reviewed international journals, but this does not mean that their research is validated immediately. It still needs to be reviewed and questioned by their scientific peers.

A policeman standing guard at a barricade at a restricted area sealed by the authorities in Lahore, Pakistan, last Thursday. It is evident that, much like the global trend in countries where Covid-19 cases have soared, Pakistan's daily cases and deaths are growing, says one of the writers. PHOTO: AGENCE FRANCE-PRESSE

Michael Tan

Philippine Daily Inquirer, The Philippines

We are truly fortunate that, in the Philippines, we have adopted masks wholeheartedly, although with some lapses in the way they are used.

We are all right with masks, but with testing, we are pretty much like the United States, with all the well-publicised criticism of our testing continuing to be haphazard and without a sense of direction.

I have written about this several times, as has my fellow columnist Mahar Mangahas: We need random testing or, to use an epidemiological term, sentinel surveillance - looking at all geographical areas and at different population groups, and not just the so-called high-risk ones.

Random (but systematic) testing is not mass testing. We do not need to test all 110 million Filipinos, but we do need to have representative geographical distribution so we can have early detection. Right now, we wait for an outbreak and then rush in to test, and we are often by then overwhelmed by the speed of its spread, as is happening now in Cebu.

What I worry about now is that even while we are improving, ever so slowly, on testing, we do not seem to be doing adequate contact tracing, which must go together with the testing. Contact tracers look at the people behind the numbers. It is through contact tracing that we have obtained some of the very important information on superspreader venues.

Editorial

The Yomiuri Shimbun, Japan

The spread of infections with the coronavirus has directly hit the vulnerabilities in Japan's politics, economy and society. The country must make all-out efforts to restore peace of mind to people's lives.

The Yomiuri Shimbun has compiled a set of proposals to build a society that is resistant to infectious diseases in preparation for the arrival of a second wave of infections.

First, the proposal calls for improving the PCR (polymerase chain reaction) testing system and increasing the number of tests to 100,000 a day. By combining it with antigen tests and other methods appropriately, it is hoped that the reality of the infection situation will be revealed.

A shortage of hospital beds must be avoided. Place people with mild symptoms in accommodation facilities, hospitalise those with moderate symptoms in priority medical institutions and those with severe symptoms in advanced medical institutions.

To increase the speed of implementing measures and delivering clear messages, the creation of a control tower initiated by the prime minister to lead infectious disease measures will be effective.

Second, as for economic stimulus measures, it has taken time to provide cash relief and loans. Efforts must be accelerated to restructure the relevant systems.

There is no point in compiling a budget unless funds are actually distributed. The government must thoroughly reflect on the situation and establish an infrastructure that enables swift budget execution.

Another task is to accelerate digitalisation, which lags behind other countries. Online handling of applications needs to be strengthened, so that people can receive benefits and loans through simple procedures.

Third, international cooperation will be essential to the development of vaccines and therapeutic drugs and the distribution of them. It is proper for Japan, as the host country preparing for the Tokyo Olympics and Paralympics, to take the lead.

Badiuzzaman Bay

The Daily Star, Bangladesh

According to a tell-all report by The Daily Star, a number of professional bodies have secured beds for their members and families at several private hospitals in Dhaka.

On June 11, the Bangladesh Judicial Service Association signed a deal with the Universal Medical College Hospital to provide treatment to lower court judges suffering from Covid-19 and other diseases.

Not to be outdone, the Bangladesh Police on May 5 "hired" an entire hospital (Impulse Hospital) for 2 months to treat its members.

Since when has it been it all right to "book" entire hospitals or hospital beds for certain people? Should we accept this as a new normal where access to treatment for the common people will be contingent on the availability of beds left by the influential?

Since March 8, when the country confirmed its first coronavirus case, there have been multiple reports of ordinary people desperately moving from one hospital to another without receiving treatment. Recently, the nurse of a private hospital in Dhaka died after being denied treatment by the very hospital she worked at.

A common thread running through these heartbreaking episodes is the victims' "ordinariness", their having no power or connections that could qualify them for treatment.

The situation has reached a point where people are simply afraid to have anything to do with sickness lest they need to confront the challenges of hospitalisation.

Editorial

Dawn, Pakistan

On multiple days since the middle of this month, official figures for coronavirus-related deaths in the country have been well over 100. According to press releases issued by the National Command and Operation Centre, 111 people lost their lives to Covid-19 on June 16 and 136 on June 17.

About a week ago, the official death toll in a single day was 153 - the highest in 24 hours since the start of the outbreak in Pakistan at the end of February. As these figures continue to climb, the daily number of tests towards the end of this month stands at an average of 28,500 - far lower than the 100,000 daily testing milestone the government has calculated for next month.

It is evident that, much like the global trend in countries where Covid-19 cases have soared, Pakistan's daily cases and deaths are growing.

Although the authorities may argue that cases and deaths here are still lower than in many of the worst-hit countries, the reality is that Pakistan is still over a month away from what the authorities and think-tanks have estimated to be the "peak phase".

As we approach that dreaded period, testing must be ramped up, and fast, so that we can have a realistic picture of the spread of Covid-19.

The View From Asia is a compilation of articles from The Straits Times' media partner Asia News Network, a grouping of 24 news media titles.

Originally posted here:
Mishandling of the Covid-19 pandemic raises concern, Asia News & Top Stories - straits times

This detailed market study covers Cart Cell Therapy Market growth potentials which can assist the stakeholders to understand key trends and prospects in Cart cell therapy market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the markets growth potential, which can help investors identify scope and opportunities. The analysis also provides details of each segment in the global Cart cell therapy market.

Get Sample Copy of This Report @https://www.quincemarketinsights.com/request-sample-61563?utm_source=Radhika/PF

According to the report, Cart cell therapy market report highlights market opportunities and competitive scenarios for Cart cell therapy on a regional and global basis. Market size estimation and forecasts have been provided based on a unique research design customized to the dynamics of the Cart cell therapy market. The Cart cell therapy market has been segmented by target antigen (cd19, cd22 and others), application (acute lymphoblastic leukemia, diffuse large b-cell lymphoma and others), end user (hospital, pharmaceuticals, clinic and others). Historic back-drop for the Cart cell therapy market has been analyzed according to organic and inorganic developments to provide precise market size estimations. Also, key factors impacting the growth of the Cart cell therapy market have been identified with potential gravity.

Regional segmentation and analysis to understand growth patterns:The market has been segmented in major regions to understand the global development and demand patterns of this market.

North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, & Rest of the World segmented the Cart cell therapy market on a regional basis. Some of the major markets in North America and Western Europe are also typical suppliers of chemicals such as specialty chemicals, bulk chemicals, and so on. The major companies in this market have their headquarters in North and Western Europe.

The Asia Pacific and the Middle East are expected to register substantial growth in the Cart cell therapy market during the forecast period. This demand is with regard to the growth of major end-use industries such as marine, oil & gas, industrial, construction & infrastructure, energy & power, automotive & transportation. Major countries in the Asia Pacific region include China, South Korea, Japan, India, Australia, and so on. Middle East includes the UAE, Saudi Arabia, Iran, Israel, Egypt, and so on.

Eastern Europe has been largely dominated by Russia and Turkey with operations of major chemical giants in the region. Rest the World that includes South America and Africa has a strong potential for the Cart cell therapy market. There have been an increasing number of investments by global companies in these regions to strengthen their presence and tap the potential market. Major economies in these regions for the Cart cell therapy market include Brazil, South Africa, Nigeria, Argentina, Colombia, and others.

This report provides:1) An overview of the global market for Cart cell therapy market and related technologies.2) Analysis of global market trends, yearly estimates and annual growth rate projections for compounds (CAGRs).3) Identification of new market opportunities and targeted consumer marketing strategies for global Cart cell therapy market.4) Analysis of R&D and demand for new technologies and new applications5) Extensive company profiles of key players in industry.

The researchers have studied the market in depth and have developed important segments such as product type, application and region. Each and every segment and its sub-segments are analyzed based on their market share, growth prospects and CAGR. Each market segment offers in-depth, both qualitative and quantitative information on market outlook.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:1. Novartis AG2. Kite Pharma3. Mustang Bio4. Sorrento Therapeutics5. CARsgen Therapeutics6. Autolus Therapeutics7. Pfizer Inc.8. Cellectis, Legend Biotech9. Bellicum Pharmaceuticals10. and others.

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-61563?utm_source=Radhika/PF

Market Segmentation:By Target Antigeno CD19o CD22o Others

By Applicationo Acute Lymphoblastic Leukemiao Diffuse Large B-Cell Lymphomao Others

By End-Usero Pharmaceuticals Companieso Hospitalo Clinico Other

By Region:North Americao By Country (US, Canada, Mexico)o By Target Antigeno By Applicationo By End User

Western Europeo By Country (Germany, UK, France, Italy, Spain, Rest of Western Europe)o By Target Antigeno By Applicationo By End User

Eastern Europeo By Country (Russia, Turkey, Rest of Eastern Europe)o By Target Antigeno By Applicationo By End User

Asia Pacifico By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)o By Target Antigeno By Applicationo By End User

Middle Easto By Country (UAE, Saudi Arabia, Qatar, Iran, Rest of Middle East)o By Target Antigeno By Applicationo By End User

Rest of the Worldo By Region (South America, Africa)o By Target Antigeno By Applicationo By End User

Reasons to Buy This Report:o Market size estimation of the cart cell therapy market on a regional and global basiso Unique research usage for market size estimation and forecast

o Profiling of major companies operating in the market with key developmentso Broad scope to cover all the possible segments helping every stakeholder in the market

Customization:We provide customization of the study to meet specific requirements:o By Segmento By Sub-segmento By Region/Country

Contact:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109,

Pune, Maharashtra 411028

Phone: IN +91 706 672 5858

US +1 208 405 2835

UK +44 121 364 6144

APAC +91 706 672 4848

Email:[emailprotected]

Web:www.quincemarketinsights.com

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

See more here:
Cart Cell Therapy Market 2020 By Players, Type, Application, Marketing Channel and Region - Owned